You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydrocodone
Accession NumberDB00956  (APRD00591, DB09475)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionNarcotic analgesic related to codeine, but more potent and more addicting by weight. It is used also as cough suppressant. [PubChem]
Structure
Thumb
Synonyms
(-)-Dihydrocodeinone
4,5-alpha-Epoxy-3-methoxy-17-methylmorphinan-6-one
Dihydrocodeinone
Hidrocodona
Hydrocodon
Hydrocodone
Hydrocodonum
Hydrocone
Hydroconum
Idrocodone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hycodan Syrupsyrup1 mgoralBristol Myers Squibb Canada1992-12-31Not applicableCanada
Hycodan Tabletstablet5 mgoralBristol Myers Squibb Canada1992-12-31Not applicableCanada
Hysingla ERtablet, extended release60 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERtablet, extended release80 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERtablet, extended release20 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERtablet, extended release100 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERtablet, extended release30 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERtablet, extended release120 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs
Hysingla ERtablet, extended release40 mg/1oralPurdue Pharma LP2015-01-15Not applicableUs
Pdp-hydrocodonesyrup1 mgoralPendopharm Division Of De Pharmascience Inc2009-03-21Not applicableCanada
Robidone 1mg/ml Syrsyrup1 mgoralWyeth Ayerst Canada Inc.1993-12-312001-11-06Canada
Robidone Syr 1mg/mlsyrup1 mgoralAyerst Laboratories1991-12-311997-08-15Canada
Zohydrocapsule, extended release15 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release10 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release50 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release40 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release20 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release15 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release50 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release30 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release20 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release10 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release40 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydrocapsule, extended release30 mg/1oralZogenix, Inc.2013-10-25Not applicableUs
Zohydro ERcapsule, extended release30 mg/1oralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERcapsule, extended release10 mg/1oralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERcapsule, extended release40 mg/1oralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERcapsule, extended release15 mg/1oralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERcapsule, extended release50 mg/1oralPernix Therapeutics2013-10-25Not applicableUs
Zohydro ERcapsule, extended release20 mg/1oralPernix Therapeutics2013-10-25Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Caldomine Dh AdulteTechnilab Pharma Inc.
Caldomine Dh EnfantTechnilab Pharma Inc.
CodofenPaladin Labs Inc
Coristine-DH LiqTechnilab Pharma Inc.
DalmacolLaboratoire Riva Inc
Dimetane Expectorant DcPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Dimetane Expectorant-DC SyrWhitehall Robins Inc.
Direct RxDIRECT RX
FlowtussMission Pharmacal Company
HycetG&W Laboratories, Inc.
HycofenixMission Pharmacal Company
HycomineBristol Myers Squibb Canada
Hycomine-SBristol Myers Squibb Canada
Hydrocodone AcetaminophenRed Pharm Drug Inc.
Hydrocodone Bit/apapMedsource Pharmaceuticals
Hydrocodone Bitartate and AcetaminophenActavis Pharma, Inc.
Hydrocodone BitartrateDIRECT RX
Hydrocodone Bitartrate and AcetaminophenPharmaceutical Associates, Inc.
Hydrocodone Bitartrate and Acetaminophen TabletsRed Pharm Drug Inc.
Hydrocodone Bitartrate and Chlorpheniramine Maleate SolutionTris Pharma Inc
Hydrocodone Bitartrate and Homatropine MethylbromidePharmaceutical Associates, Inc.
Hydrocodone Bitartrate and IbuprofenTeva Pharmaceuticals USA Inc
Hydrocodone Bitartrate and Pseudoephedrine Hydrochloride SolutionTris Pharma Inc
Hydrocodone Bitartrate With AcetaminophenApotheca Inc.
Hydrocodone Bitartrate, Chlorpheniramine Maleate and Pseudoephedrine HydrochloridePaddock Laboratories, LLC
Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Pseudoephedrine HClCypress Pharmaceutical, Inc.
Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Pseudoephedrine Hydrochloride Oral SolutionTris Pharma Inc
Hydrocodone Bitatrate and AcetaminophenActavis Pharma, Inc.
Hydrocodone Polistirex and Chlorpheniramine PolisitrexAtlantic Biologicals Corps
Hydrocodone Polistirex and Chlorpheniramine PolistirexPhysicians Total Care, Inc.
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-releaseAristos Phamaceuticals, Inc.
Hydrocodone Polistirex and Chlorpheniramine Polistirex PennkineticAtlantic Biologicals Corps
Hydrocodone/apapPharm Pak, Inc.
HydrometActavis Mid Atlantic LLC
IbucodonePaladin Labs Inc
IbudonePoly Pharmaceuticals
LorcetCardinal Health
Lorcet 10/650Rx Pak Division Of Mc Kesson Corporation
Lorcet HdMayne Pharma Inc.
Lorcet PlusCardinal Health
LortabECR Pharmaceuticals
Lortab 10/325UCB, Inc.
Lortab 5/325UCB, Inc.
Lortab 7.5/325UCB, Inc.
MaxidoneWatson Pharma, Inc.
Mercodol With DecaprynAventis Pharma Inc
NorcoActavis Pharma, Inc.
Novahistex DhSanofi Aventis Canada Inc
Novahistex Dh ExpectorantAventis Pharma Inc
Novahistine DhSanofi Aventis Canada Inc
ObredonNovotec Pharma Llc
Ratio-calmydoneTeva Canada Limited
Ratio-coristex-DHRatiopharm Inc Division Of Teva Canada Limited
ReprexainStat Rx USA
ReziraHawthorn Pharmaceuticals, Inc.
Theracodophen-325Physician Therapeutics Llc
Theracodophen-650Physician Therapeutics Llc
Theracodophen-750Physician Therapeutics Llc
Theracodophen-low-90Physician Therapeutics Llc
Triaminic Expectorant Dh SyrupNovartis Consumer Health Canada Inc.
Tussaminic Dh Forte SyrupNovartis Consumer Health Canada Inc.
Tussaminic Dh Pediatric SyrupNovartis Consumer Health Canada Inc.
TussicapsECR Pharmaceuticals
TussigonPfizer Laboratories Div Pfizer Inc
TussionexSanofi Aventis Canada Inc
Tussionex PennkineticUnither Manufacturing, LLC
Vasofrinic DhLaboratoires Trianon Inc
VicodinAbb Vie Inc.
Vicodin EsAbb Vie Inc.
Vicodin HpAbb Vie Inc.
VicoprofenAbb Vie Inc.
VituzHawthorn Pharmaceuticals, Inc.
XodolRebel Distributors Corp.
Xylon 10Sircle Laboratories, Llc
ZamicetPharmaceutical Associates, Inc.
ZutriproHawthorn Pharmaceuticals, Inc.
ZydoneSTAT Rx USA LLC
Salts
Name/CASStructureProperties
Hydrocodone bitartrate
ThumbNot applicableDBSALT001233
Hydrocodone polistirex
ThumbNot applicableDBSALT001602
Categories
UNII6YKS4Y3WQ7
CAS number125-29-1
WeightAverage: 299.3642
Monoisotopic: 299.152143543
Chemical FormulaC18H21NO3
InChI KeyInChIKey=LLPOLZWFYMWNKH-CMKMFDCUSA-N
InChI
InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1
IUPAC Name
(1S,5R,13R,17R)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7(18),8,10-trien-14-one
SMILES
[H][C@@]12OC3=C(OC)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassMorphinans
Sub ClassNot Available
Direct ParentMorphinans
Alternative Parents
Substituents
  • Morphinan
  • Benzylisoquinoline
  • Phenanthrene
  • Isoquinolone
  • Tetralin
  • Benzofuran
  • Anisole
  • Aralkylamine
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Piperidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor relief of moderate to moderately severe pain. Also used for the symptomatic relief of nonproductive cough, alone or in combination with other antitussives or expectorants.
PharmacodynamicsHydrocodone, a semisynthetic opiate agonist and hydrogenated ketone derivative, is similar to other phenanthrene derivatives, such as codeine. Used as an analgesic, hydrocodone is combined with acetaminophen, ibuprofen, or aspirin to treat pain. Used as an antitussive, hydrocodone is combined with phenylephrine, pseudoephedrine, phenylpropanolamine, guaifenesin, pyrilamine, pheniramine, or chlorpheniramine. Opiate agonists exert their principal pharmacologic effect at specific receptor binding sites in the CNS and other tissues. There are several subtypes of opiate receptors including the mu receptor (localized in pain modulating regions of the CNS), the kappa receptor (localized in the deep layers of the cerebral cortex), the delta receptor (localized in the limbic regions of the CNS), and the sigma receptor (thought to mediate the dysphoric and psychotomimetic effects of some opiate partial agonists). Agonist activity at the mu or kappa receptor can result in analgesia, miosis, and/or decreased body temperature. Agonist activity at the mu receptor can also result in suppression of opiate withdrawal, whereas antagonist activity can result in precipitation of withdrawal. Opiate agonists act at several sites within the CNS involving several systems of neurotransmitters to produce analgesia, but the precise mechanism of action has not been fully determined. Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli nor the conduction of impulses along peripheral nerves. Instead, they alter the perception of pain at the spinal cord and higher levels in the CNS and the person's emotional response to pain.
Mechanism of actionHydrocodone acts as a weak agonist at OP1, OP2, and OP3 opiate receptors within the central nervous system (CNS). Hydrocodone primarily affects OP3 receptors, which are coupled with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine, and noradrenaline is inhibited. Opioids such as hydrocodone also inhibit the release of vasopressin, somatostatin, insulin, and glucagon. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingAs most agents in the 5-ring morphinan group of semi-synthetic opioids bind plasma protein to a similar degree (range 19% [hydromorphone] to 45% [oxycodone]), hydrocodone is expected to fall within this range.
Metabolism

Hepatic and also in intestinal mucosa.

SubstrateEnzymesProduct
Hydrocodone
hydromorphoneDetails
Hydrocodone
norhydrocodoneDetails
Route of eliminationNot Available
Half life1.25-3 hours
ClearanceNot Available
ToxicitySymptoms of overdose include respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, dizziness, ringing in the ears, confusion, blurred vision, eye problems, cold and clammy skin, and sometimes bradycardia and hypotension. In severe overdose, apnea, circulatory collapse, cardiac arrest and death may occur. LD50=85.7mg/kg (subcutaneous, in mice).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Hydrocodone Action PathwayDrug actionSMP00411
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9984
Caco-2 permeable+0.8621
P-glycoprotein substrateSubstrate0.8253
P-glycoprotein inhibitor IInhibitor0.6425
P-glycoprotein inhibitor IINon-inhibitor0.8664
Renal organic cation transporterInhibitor0.6604
CYP450 2C9 substrateNon-substrate0.8546
CYP450 2D6 substrateSubstrate0.8997
CYP450 3A4 substrateSubstrate0.8168
CYP450 1A2 substrateNon-inhibitor0.8207
CYP450 2C9 inhibitorNon-inhibitor0.9412
CYP450 2D6 inhibitorInhibitor0.6629
CYP450 2C19 inhibitorNon-inhibitor0.8402
CYP450 3A4 inhibitorNon-inhibitor0.7625
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8675
Ames testNon AMES toxic0.7735
CarcinogenicityNon-carcinogens0.9419
BiodegradationNot ready biodegradable0.984
Rat acute toxicity3.0914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9024
hERG inhibition (predictor II)Non-inhibitor0.8165
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Syruporal1 mg
Tabletoral5 mg
Liquidoral
Solutionoral
Suspension, extended releaseoral
Suspensionoral
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral120 mg/1
Tablet, extended releaseoral20 mg/1
Tablet, extended releaseoral30 mg/1
Tablet, extended releaseoral40 mg/1
Tablet, extended releaseoral60 mg/1
Tablet, extended releaseoral80 mg/1
Syruporal
Kit
Capsule, extended releaseoral
Tablet (extended-release)oral
Tabletoral
Tablet, coatedoral
Tablet, film coatedoral
Capsule, extended releaseoral10 mg/1
Capsule, extended releaseoral15 mg/1
Capsule, extended releaseoral20 mg/1
Capsule, extended releaseoral30 mg/1
Capsule, extended releaseoral40 mg/1
Capsule, extended releaseoral50 mg/1
Prices
Unit descriptionCostUnit
Hydrocodone-Acetaminophen 7.5-500 mg/15ml Solution 473ml Bottle60.97USD bottle
Hydrocodone-Ibuprofen 7.5-200 mg tablet1.13USD tablet
Hydrocodone-Acetaminophen 10-750 mg tablet1.1USD tablet
Hydrocodone-Acetaminophen 7.5-325 mg tablet0.63USD tablet
Hydrocodone-Acetaminophen 10-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 5-325 mg tablet0.57USD tablet
Hydrocodone-Acetaminophen 10-660 mg tablet0.53USD tablet
Hydrocodone-Acetaminophen 10-500 mg tablet0.5USD tablet
Hydrocodone-Acetaminophen 10-650 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 7.5-500 mg tablet0.47USD tablet
Hydrocodone-Acetaminophen 2.5-500 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 7.5-750 mg tablet0.43USD tablet
Hydrocodone-Acetaminophen 5-500 mg tablet0.4USD tablet
Hydrocodone-Acetaminophen 7.5-650 mg tablet0.16USD tablet
Hydrocodone-Homatropine 5-1.5 mg/5ml Syrup0.15USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6228398 No1999-11-012019-11-01Us
US6348216 No1997-06-102017-06-10Us
US6488963 No1997-06-242017-06-24Us
US6599531 No1997-06-102017-06-10Us
US6733783 No2001-10-302021-10-30Us
US6902742 No1999-11-012019-11-01Us
US8309060 No2003-11-202023-11-20Us
US8361499 No2001-10-302021-10-30Us
US8529948 No2002-08-062022-08-06Us
US8551520 No2001-10-302021-10-30Us
US8647667 No2001-10-302021-10-30Us
US8808740 No2011-12-212031-12-21Us
US9023401 No2001-10-302021-10-30Us
US9056052 No2001-10-302021-10-30Us
US9060940 No2001-10-302021-10-30Us
US9084816 No2007-08-242027-08-24Us
US9095614 No2007-08-242027-08-24Us
US9095615 No2007-08-242027-08-24Us
US9132096 No2014-09-122034-09-12Us
US9198863 No2001-10-302021-10-30Us
US9205056 No2001-10-302021-10-30Us
US9265760 No2013-07-232033-07-23Us
US9289391 No2001-10-302021-10-30Us
US9326982 No2013-07-252033-07-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point198 °CPhysProp
water solubilityInsolubleNot Available
logP1.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.797 mg/mLALOGPS
logP2.13ALOGPS
logP1.96ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)18ChemAxon
pKa (Strongest Basic)8.61ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area38.77 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.74 m3·mol-1ChemAxon
Polarizability32.05 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.3 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0005-6970000000-3ba3e105098639cd6091View in MoNA
References
Synthesis Reference

Anne M. Hailes, Christopher E. French, Neil C. Bruce, “Morphinone reductase for the preparation of hydromorphone and hydrocodone.” U.S. Patent US5571685, issued November, 1990.

US5571685
General ReferencesNot Available
External Links
ATC CodesR05DA03
AHFS Codes
  • 48:08.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.8 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydrocodone.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Hydrocodone.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Hydrocodone is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Hydrocodone.
AbirateroneThe metabolism of Hydrocodone can be decreased when combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Hydrocodone.
AcepromazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Acetazolamide.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Hydrocodone.
adipiplonThe risk or severity of adverse effects can be increased when Hydrocodone is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hydrocodone.
AlimemazineAlimemazine may increase the hypotensive activities of Hydrocodone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alphacetylmethadol.
AlprazolamThe serum concentration of Hydrocodone can be increased when it is combined with Alprazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alprazolam.
AlvimopanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amiloride.
AmiodaroneThe serum concentration of Hydrocodone can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amitriptyline.
AmlodipineThe serum concentration of Hydrocodone can be increased when it is combined with Amlodipine.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Hydrocodone which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amobarbital.
AmoxapineHydrocodone may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Hydrocodone.
AmperozideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Hydrocodone.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hydrocodone.
AprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Aripiprazole.
ArmodafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Armodafinil.
ArtemetherThe serum concentration of Hydrocodone can be decreased when it is combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Asenapine.
AtazanavirThe serum concentration of Hydrocodone can be increased when it is combined with Atazanavir.
AtomoxetineThe serum concentration of Hydrocodone can be increased when it is combined with Atomoxetine.
AtorvastatinThe serum concentration of Hydrocodone can be increased when it is combined with Atorvastatin.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hydrocodone.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Hydrocodone.
AzaperoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Azaperone.
AzelastineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Hydrocodone.
AzosemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Barbital.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Hydrocodone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Hydrocodone.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hydrocodone.
BenzocaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Hydrocodone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Benzyl alcohol.
BetaxololThe metabolism of Hydrocodone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Hydrocodone can be decreased when it is combined with Bexarotene.
BicalutamideThe serum concentration of Hydrocodone can be increased when it is combined with Bicalutamide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Hydrocodone.
BoceprevirThe serum concentration of Hydrocodone can be increased when it is combined with Boceprevir.
BortezomibThe serum concentration of Hydrocodone can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Hydrocodone can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
BrimonidineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Brotizolam.
BumetanideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hydrocodone.
BuprenorphineBuprenorphine may decrease the analgesic activities of Hydrocodone.
BuprenorphineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Buprenorphine.
BupropionThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Bupropion resulting in a loss in efficacy.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Hydrocodone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hydrocodone.
ButacaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Hydrocodone.
ButorphanolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Butorphanol.
CalcitriolThe serum concentration of Hydrocodone can be decreased when it is combined with Calcitriol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Canrenoic acid.
CarbamazepineThe serum concentration of Hydrocodone can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Hydrocodone.
CelecoxibThe metabolism of Hydrocodone can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Hydrocodone can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hydrocodone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chloroprocaine.
ChloroquineThe metabolism of Hydrocodone can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorphenamine.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Hydrocodone.
ChlorphentermineChlorphentermine may increase the analgesic activities of Hydrocodone.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Hydrocodone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Hydrocodone can be decreased when combined with Cholecalciferol.
CilostazolThe serum concentration of Hydrocodone can be increased when it is combined with Cilostazol.
CimetidineThe serum concentration of Hydrocodone can be increased when it is combined with Cimetidine.
CinacalcetThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cinacalcet resulting in a loss in efficacy.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Hydrocodone.
CiprofloxacinThe serum concentration of Hydrocodone can be increased when it is combined with Ciprofloxacin.
CitalopramHydrocodone may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Hydrocodone can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Hydrocodone can be increased when it is combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clidinium.
ClobazamThe serum concentration of Hydrocodone can be decreased when it is combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Hydrocodone is combined with clomethiazole.
ClomipramineHydrocodone may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Hydrocodone can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hydrocodone.
ClotrimazoleThe serum concentration of Hydrocodone can be increased when it is combined with Clotrimazole.
ClozapineThe metabolism of Hydrocodone can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Clozapine.
CobicistatThe serum concentration of Hydrocodone can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Cocaine resulting in a loss in efficacy.
CocaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydrocodone.
ConivaptanThe serum concentration of Hydrocodone can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Conivaptan.
CrizotinibThe serum concentration of Hydrocodone can be increased when it is combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Hydrocodone.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydrocodone.
CyclosporineThe serum concentration of Hydrocodone can be increased when it is combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Dabrafenib.
DalfopristinThe serum concentration of Hydrocodone can be increased when it is combined with Dalfopristin.
DanazolThe serum concentration of Hydrocodone can be increased when it is combined with Danazol.
DantroleneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hydrocodone.
DapoxetineHydrocodone may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Hydrocodone.
DarunavirThe serum concentration of Hydrocodone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Hydrocodone can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.
DelavirdineThe serum concentration of Hydrocodone can be increased when it is combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desflurane.
DesipramineThe metabolism of Hydrocodone can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hydrocodone.
DesmopressinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Desmopressin.
DesvenlafaxineThe serum concentration of Hydrocodone can be decreased when it is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Detomidine.
DexamethasoneThe serum concentration of Hydrocodone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hydrocodone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydrocodone.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Hydrocodone.
DextromoramideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydrocodone.
DezocineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Hydrocodone.
DicloxacillinThe serum concentration of Hydrocodone can be decreased when it is combined with Dicloxacillin.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.
DifenoxinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dihydrocodeine.
DihydroergotamineThe serum concentration of Hydrocodone can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dihydromorphine.
DiltiazemThe serum concentration of Hydrocodone can be increased when it is combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Hydrocodone can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Doxepin.
DoxycyclineThe serum concentration of Hydrocodone can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DoxylamineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Hydrocodone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
DronedaroneThe serum concentration of Hydrocodone can be increased when it is combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Hydrocodone.
DrospirenoneThe serum concentration of Hydrocodone can be decreased when it is combined with Drospirenone.
DrospirenoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Drotebanol.
DuloxetineThe metabolism of Hydrocodone can be decreased when combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hydrocodone.
EcgonineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Hydrocodone is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Hydrocodone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Efonidipine.
EliglustatThe metabolism of Hydrocodone can be decreased when combined with Eliglustat.
EluxadolineHydrocodone may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Hydrocodone.
EntacaponeThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Entacapone.
EnzalutamideThe serum concentration of Hydrocodone can be decreased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Eplerenone.
ErythromycinThe serum concentration of Hydrocodone can be increased when it is combined with Erythromycin.
EscitalopramHydrocodone may increase the serotonergic activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Estazolam.
EstradiolThe serum concentration of Hydrocodone can be decreased when it is combined with Estradiol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Hydrocodone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid.
EthanolHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hydrocodone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hydrocodone.
EthosuximideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Hydrocodone.
EtoperidoneHydrocodone may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etorphine.
EtravirineThe serum concentration of Hydrocodone can be decreased when it is combined with Etravirine.
ExemestaneThe serum concentration of Hydrocodone can be decreased when it is combined with Exemestane.
EzogabineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ezogabine.
FelbamateThe serum concentration of Hydrocodone can be decreased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fencamfamine.
FenfluramineHydrocodone may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydrocodone.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hydrocodone.
FexofenadineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Flibanserin.
FluconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Flunitrazepam.
FluoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Fluoxetine resulting in a loss in efficacy.
FluoxetineHydrocodone may increase the serotonergic activities of Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hydrocodone.
FluphenazineFluphenazine may increase the hypotensive activities of Hydrocodone.
FluphenazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Hydrocodone.
FluspirileneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fluticasone Propionate.
FluvoxamineThe serum concentration of Hydrocodone can be increased when it is combined with Fluvoxamine.
FluvoxamineHydrocodone may increase the serotonergic activities of Fluvoxamine.
FosamprenavirThe serum concentration of Hydrocodone can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Hydrocodone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Hydrocodone can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Fospropofol.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Hydrocodone.
FurosemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Furosemide.
Fusidic AcidThe serum concentration of Hydrocodone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Hydrocodone is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hydrocodone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Glutethimide.
Glycerol PhenylbutyrateThe serum concentration of Hydrocodone can be increased when it is combined with Glycerol Phenylbutyrate.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Hydrocodone.
GriseofulvinThe serum concentration of Hydrocodone can be decreased when it is combined with Griseofulvin.
GuanfacineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Hydrocodone.
HaloperidolThe metabolism of Hydrocodone can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydrocodone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hexobarbital.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Hydrocodone.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Hydrocodone.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocodone can be decreased when it is combined with Hydrocortisone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydrocodone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hydrocodone.
IdelalisibThe serum concentration of Hydrocodone can be increased when it is combined with Idelalisib.
IloperidoneThe serum concentration of Hydrocodone can be increased when it is combined with Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Iloperidone.
ImatinibThe serum concentration of Hydrocodone can be increased when it is combined with Imatinib.
ImipramineThe metabolism of Hydrocodone can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Imipramine.
IndalpineHydrocodone may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Indapamide.
IndinavirThe serum concentration of Hydrocodone can be increased when it is combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Hydrocodone.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Hydrocodone.
IsavuconazoniumThe serum concentration of Hydrocodone can be decreased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Hydrocodone.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Hydrocodone.
IsoniazidThe serum concentration of Hydrocodone can be increased when it is combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Isosorbide.
IsradipineThe serum concentration of Hydrocodone can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Hydrocodone can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ketobemidone.
KetoconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Hydrocodone is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Lamotrigine.
LapatinibThe serum concentration of Hydrocodone can be increased when it is combined with Lapatinib.
LevetiracetamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Levomethadyl Acetate.
LevomilnacipranHydrocodone may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydrocodone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Hydrocodone.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Hydrocodone.
LithiumThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Lofentanil.
LomitapideThe serum concentration of Hydrocodone can be increased when it is combined with Lomitapide.
LopinavirThe serum concentration of Hydrocodone can be decreased when it is combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Hydrocodone.
LorcaserinThe metabolism of Hydrocodone can be decreased when combined with Lorcaserin.
LovastatinThe serum concentration of Hydrocodone can be increased when it is combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Hydrocodone.
Lu AA21004Hydrocodone may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Hydrocodone.
LuliconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Hydrocodone can be decreased when it is combined with Lumefantrine.
LurasidoneThe serum concentration of Hydrocodone can be increased when it is combined with Lurasidone.
LurasidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Maprotiline.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Hydrocodone.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hydrocodone.
MeclizineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Medetomidine.
Medroxyprogesterone acetateThe serum concentration of Hydrocodone can be decreased when it is combined with Medroxyprogesterone acetate.
MelatoninThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Hydrocodone.
MepivacaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hydrocodone.
MersalylThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Hydrocodone.
MesoridazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metaxalone.
MethadoneThe metabolism of Hydrocodone can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Hydrocodone.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Hydrocodone.
MethapyrileneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Hydrocodone.
MethotrimeprazineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Methotrimeprazine resulting in a loss in efficacy.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methyclothiazide.
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Hydrocodone.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hydrocodone.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Hydrocodone.
MetolazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.
MetoprololThe metabolism of Hydrocodone can be decreased when combined with Metoprolol.
MetyraponeThe serum concentration of Hydrocodone can be decreased when it is combined with Metyrapone.
MetyrosineHydrocodone may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Hydrocodone.
MifepristoneThe serum concentration of Hydrocodone can be increased when it is combined with Mifepristone.
MilnacipranHydrocodone may increase the serotonergic activities of Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Hydrocodone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
MirabegronThe metabolism of Hydrocodone can be decreased when combined with Mirabegron.
MirtazapineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Hydrocodone.
MitotaneThe serum concentration of Hydrocodone can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydrocodone.
ModafinilThe serum concentration of Hydrocodone can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Hydrocodone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydrocodone.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Hydrocodone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
NabiloneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nabilone.
NafcillinThe serum concentration of Hydrocodone can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Hydrocodone.
NalbuphineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Hydrocodone can be decreased when used in combination with Naltrexone.
NefazodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Hydrocodone can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Hydrocodone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Hydrocodone can be decreased when it is combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydrocodone.
NicardipineThe serum concentration of Hydrocodone can be increased when it is combined with Nicardipine.
NilotinibThe serum concentration of Hydrocodone can be increased when it is combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nitrous oxide.
NorgestimateThe serum concentration of Hydrocodone can be decreased when it is combined with Norgestimate.
NormethadoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Nortriptyline.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Hydrocodone.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Hydrocodone.
OlanzapineHydrocodone may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hydrocodone.
OlaparibThe serum concentration of Hydrocodone can be increased when it is combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hydrocodone.
OpiumThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Opium.
OritavancinThe serum concentration of Hydrocodone can be decreased when it is combined with Oritavancin.
OrphenadrineHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hydrocodone.
OsanetantThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Osanetant.
OsimertinibThe serum concentration of Hydrocodone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Hydrocodone.
OxcarbazepineThe serum concentration of Hydrocodone can be decreased when it is combined with Oxcarbazepine.
OxprenololThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Hydrocodone.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hydrocodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydrocodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hydrocodone.
PaclitaxelThe serum concentration of Hydrocodone can be decreased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Hydrocodone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Paliperidone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydrocodone.
PanobinostatThe metabolism of Hydrocodone can be decreased when combined with Panobinostat.
ParaldehydeHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Hydrocodone.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydrocodone.
ParoxetineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.
ParoxetineHydrocodone may increase the serotonergic activities of Paroxetine.
PazopanibThe serum concentration of Hydrocodone can be increased when it is combined with Pazopanib.
Peginterferon alfa-2bThe serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Hydrocodone.
PentazocinePentazocine may decrease the analgesic activities of Hydrocodone.
PentazocineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pentazocine.
PentobarbitalThe serum concentration of Hydrocodone can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pentobarbital.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hydrocodone.
PerampanelThe serum concentration of Hydrocodone can be decreased when it is combined with Perampanel.
PerampanelThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Hydrocodone.
PerphenazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydrocodone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Hydrocodone.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Hydrocodone.
PhenobarbitalThe serum concentration of Hydrocodone can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Hydrocodone.
PhenterminePhentermine may increase the analgesic activities of Hydrocodone.
PhenytoinThe serum concentration of Hydrocodone can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pimozide.
PioglitazoneThe serum concentration of Hydrocodone can be decreased when it is combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hydrocodone.
PipotiazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.
PiretanideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydrocodone.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Hydrocodone.
PizotifenThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pomalidomide.
PosaconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Posaconazole.
PotassiumThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium Citrate.
PramipexoleHydrocodone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Prazepam.
PrednisoneThe serum concentration of Hydrocodone can be decreased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Hydrocodone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Hydrocodone.
PrimidoneThe serum concentration of Hydrocodone can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Hydrocodone.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Hydrocodone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hydrocodone.
PromazinePromazine may increase the hypotensive activities of Hydrocodone.
PromazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Hydrocodone.
PromethazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Hydrocodone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Hydrocodone.
PropofolThe serum concentration of Hydrocodone can be increased when it is combined with Propofol.
PropofolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Hydrocodone is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Quinethazone.
QuinidineThe serum concentration of Hydrocodone can be increased when it is combined with Quinidine.
QuinineThe metabolism of Hydrocodone can be decreased when combined with Quinine.
QuinupristinThe serum concentration of Hydrocodone can be increased when it is combined with Quinupristin.
RamelteonThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ramelteon.
RamosetronHydrocodone may increase the constipating activities of Ramosetron.
RanolazineThe serum concentration of Hydrocodone can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Hydrocodone.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydrocodone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hydrocodone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hydrocodone.
RifabutinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Hydrocodone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Hydrocodone can be decreased when it is combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Hydrocodone.
RitonavirThe serum concentration of Hydrocodone can be increased when it is combined with Ritonavir.
RolapitantThe metabolism of Hydrocodone can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Romifidine.
RopiniroleHydrocodone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Hydrocodone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hydrocodone.
RotigotineHydrocodone may increase the sedative activities of Rotigotine.
RufinamideThe serum concentration of Hydrocodone can be decreased when it is combined with Rufinamide.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Hydrocodone is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Hydrocodone.
SaquinavirThe serum concentration of Hydrocodone can be increased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hydrocodone.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydrocodone.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Hydrocodone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Hydrocodone.
SertindoleThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Sertindole.
SertralineHydrocodone may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Hydrocodone can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Sevoflurane.
SildenafilThe serum concentration of Hydrocodone can be increased when it is combined with Sildenafil.
SiltuximabThe serum concentration of Hydrocodone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Hydrocodone can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Sodium oxybate.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hydrocodone.
SpironolactoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Spironolactone.
St. John's WortThe serum concentration of Hydrocodone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Stiripentol resulting in a loss in efficacy.
StiripentolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Hydrocodone.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrocodone.
SulfisoxazoleThe serum concentration of Hydrocodone can be increased when it is combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hydrocodone.
SuvorexantThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tasimelteon.
TelaprevirThe serum concentration of Hydrocodone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Hydrocodone can be increased when it is combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Hydrocodone.
TerbinafineThe serum concentration of Hydrocodone can be decreased when it is combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tetrodotoxin.
ThalidomideHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Hydrocodone.
TheobromineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Hydrocodone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Hydrocodone.
ThioridazineThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Thioridazine resulting in a loss in efficacy.
ThioridazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tiagabine.
TicagrelorThe serum concentration of Hydrocodone can be increased when it is combined with Ticagrelor.
TiclopidineThe serum concentration of Hydrocodone can be increased when it is combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tiletamine.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Hydrocodone.
TipranavirThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Tipranavir resulting in a loss in efficacy.
TizanidineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tizanidine.
TocilizumabThe serum concentration of Hydrocodone can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tolcapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Hydrocodone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hydrocodone.
TolvaptanThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tolvaptan.
TopiramateThe serum concentration of Hydrocodone can be decreased when it is combined with Topiramate.
TopiramateThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Topiramate.
TorasemideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydrocodone.
TrametinibThe serum concentration of Hydrocodone can be decreased when it is combined with Trametinib.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Hydrocodone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hydrocodone.
TrazodoneHydrocodone may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Hydrocodone.
TriamtereneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Hydrocodone.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Hydrocodone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Hydrocodone.
TriflupromazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hydrocodone.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hydrocodone.
TrimipramineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Triprolidine.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hydrocodone.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hydrocodone.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hydrocodone.
UlaritideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Hydrocodone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Hydrocodone.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.
VemurafenibThe serum concentration of Hydrocodone can be decreased when it is combined with Vemurafenib.
VenlafaxineThe serum concentration of Hydrocodone can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Hydrocodone can be increased when it is combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Vigabatrin.
VilazodoneHydrocodone may increase the serotonergic activities of Vilazodone.
VoriconazoleThe serum concentration of Hydrocodone can be increased when it is combined with Voriconazole.
VortioxetineHydrocodone may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Hydrocodone.
XylazineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ziconotide.
ZimelidineHydrocodone may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe serum concentration of Hydrocodone can be increased when it is combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Hydrocodone.
ZonisamideThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with food.
  • To avoid constipation: increase your daily intake of fiber (beans, whole grains, vegetables).

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC: The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. [PubMed:10640321 ]
  3. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875 ]
  4. Hennies HH, Friderichs E, Schneider J: Receptor binding, analgesic and antitussive potency of tramadol and other selected opioids. Arzneimittelforschung. 1988 Jul;38(7):877-80. [PubMed:2849950 ]
  5. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248 ]
  6. Stoops WW, Hatton KW, Lofwall MR, Nuzzo PA, Walsh SL: Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies. Psychopharmacology (Berl). 2010 Oct;212(2):193-203. doi: 10.1007/s00213-010-1942-4. Epub 2010 Jul 28. [PubMed:20665209 ]
  7. Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr: The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008 Dec 1;98(3):191-202. doi: 10.1016/j.drugalcdep.2008.05.007. Epub 2008 Jul 7. [PubMed:18606504 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201. Epub 2005 Nov 16. [PubMed:16291875 ]
  2. Thompson CM, Wojno H, Greiner E, May EL, Rice KC, Selley DE: Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther. 2004 Feb;308(2):547-54. Epub 2003 Nov 4. [PubMed:14600248 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. [PubMed:14998425 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 29, 2016 03:23